Similar articles for PMID: 32156618

Year	Number of Results
2015	3
2016	18
2017	20
2018	19
2019	14
2020	12
2021	9
2022	2
2024	0

1

Crushed application of sofosbuvir and velpatasvir in a patient with swallowing disorder.

van Seyen M, Samson AD, Cullen L, Eastick K, Knol H, Colbers A, Burger DM. van Seyen M, et al. Int J Antimicrob Agents. 2020 Jun;55(6):105934. doi: 10.1016/j.ijantimicag.2020.105934. Epub 2020 Mar 7. Int J Antimicrob Agents. 2020. PMID: 32156618 No abstract available.

2

Effectiveness of crushed sofosbuvir-velpatasvir in a patient with dysphagia.

Mogul A, Teixeira E, McAuliffe L, Promrat K, Zullo AR. Mogul A, et al. Am J Health Syst Pharm. 2020 Mar 5;77(6):417-418. doi: 10.1093/ajhp/zxz326. Am J Health Syst Pharm. 2020. PMID: 31930300 No abstract available.

3

Therapeutic Drug Monitoring-Guided Crushed Sofosbuvir-Velpatasvir Treatment: A Case Study.

Lalanne S, Jézéquel C, Tron C, Verdier MC, Mercerolle M, Pronier C, Guyader D, Lemaitre F. Lalanne S, et al. Ther Drug Monit. 2020 Apr;42(2):163-164. doi: 10.1097/FTD.0000000000000718. Ther Drug Monit. 2020. PMID: 32195986

4

Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.

Younossi ZM, Stepanova M, Charlton M, Curry MP, O'Leary JG, Brown RS, Hunt S. Younossi ZM, et al. Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132. doi: 10.1016/S2468-1253(16)30009-7. Epub 2016 Aug 3. Lancet Gastroenterol Hepatol. 2016. PMID: 28404069 Clinical Trial.

5

Sofosbuvir/velpatasvir (Epclusa) for hepatitis C.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2016 Aug 15;58(1501):107-8. Med Lett Drugs Ther. 2016. PMID: 27508349 No abstract available.

6

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.

Mir F, Kahveci AS, Ibdah JA, Tahan V. Mir F, et al. Drug Des Devel Ther. 2017 Feb 23;11:497-502. doi: 10.2147/DDDT.S130945. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28260862 Free PMC article. Review.

7

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.

Chahine EB, Sucher AJ, Hemstreet BA. Chahine EB, et al. Ann Pharmacother. 2017 Jan;51(1):44-53. doi: 10.1177/1060028016668897. Epub 2016 Oct 1. Ann Pharmacother. 2017. PMID: 27609942 Review.

8

Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

Buggisch P, Wursthorn K, Stoehr A, Atanasov PK, Supiot R, Lee J, Ting J, Petersen J. Buggisch P, et al. PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019. PLoS One. 2019. PMID: 30946776 Free PMC article.

9

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ. Grebely J, et al. Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23. Clin Infect Dis. 2016. PMID: 27553377 Free PMC article. Clinical Trial.

10

Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.

Jones KM, Shelton ME, Soldano AC, Campbell J. Jones KM, et al. JAMA Dermatol. 2018 Sep 1;154(9):1094-1096. doi: 10.1001/jamadermatol.2018.2379. JAMA Dermatol. 2018. PMID: 30140911 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year